Author: Dr. Terushkin, MD, FACS
Key Takeaway:
🟢 FDA-approved for children and adolescents aged 10+ with type 2 diabetes
🟢 Used with diet and exercise to improve glycemic control
🟢 Sustained HbA1c reduction demonstrated for up to one year
🟢 Meaningful BMI reduction, addressing obesity and metabolic risk
🟢 Once-weekly, non-insulin treatment option for eligible pediatric patients
The U.S. Food and Drug Administration (FDA) has updated the prescribing label for Mounjaro, manufactured by Eli Lilly, to include children and adolescents aged 10 years and older with type 2 diabetes.
Per a revised FDA-approved package insert dated December 2025, Mounjaro is indicated in this age group as an adjunct to diet and exercise to improve glycemic control. The change appears in the Indications and Usage section and was implemented via formal labeling, without a separate FDA or company press announcement.
Pediatric type 2 diabetes is increasing and often progresses more rapidly than adult-onset disease. Historically, treatment options for children have been limited, frequently relying on metformin or early insulin use.
This expanded indication introduces a once-weekly, dual-incretin therapy earlier in the disease course—potentially improving long-term metabolic outcomes when combined with nutrition, physical activity, and ongoing clinical monitoring.
The FDA decision is supported by results from a Lilly-sponsored pediatric clinical trial, the first to evaluate tirzepatide in patients aged 10–17 years with type 2 diabetes.
Findings presented at a medical meeting and reported by Reuters include:
Together, these outcomes address both hyperglycemia and excess weight—two central drivers of early complications in pediatric diabetes.
Mounjaro contains tirzepatide, a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist.
By activating both incretin pathways, tirzepatide provides more comprehensive metabolic control than therapies that target GLP-1 alone—an important advantage in children and adolescents, where insulin resistance and obesity commonly coexist.
The pediatric safety profile of Mounjaro is generally consistent with adult experience. Commonly reported side effects include:
Most events are mild to moderate and occur during dose escalation. As with other GLP-1–based therapies, Mounjaro is not appropriate for all patients, including those with a personal or family history of medullary thyroid carcinoma or MEN2. Careful medical evaluation and monitoring are essential.
With FDA approval now extended to pediatric patients aged 10 and older:
Families should confirm benefits directly with their insurer and discuss assistance programs when applicable.
Out-of-pocket expenses for Mounjaro may include:
Families should ask their pharmacy and insurer for an estimation of costs before starting therapy.
In adult medicine, GLP-1/GIP–based therapy with tirzepatide has already transformed metabolic care. Many clinics across the United States use tirzepatide-based treatment to address obesity and related metabolic conditions in adults, reflecting strong evidence that dual-incretin therapy can improve weight, insulin resistance, and cardiometabolic risk factors.
While Mounjaro is approved for type 2 diabetes, tirzepatide’s dual GLP-1/GIP mechanism has driven widespread clinical adoption in adult metabolic programs, underscoring the broader role of incretin therapy in modern obesity and diabetes management under appropriate regulatory indications.
When type 2 diabetes begins in childhood, patients face decades of potential complications. Therapies that address both blood sugar and excess weight early may significantly alter disease trajectory. The pediatric approval of Mounjaro allows clinicians to apply a proven dual-incretin approach sooner, alongside lifestyle intervention and careful follow-up.
Sergey Terushkin, MD, FACS
Writes for: Florida Surgery And Weight Loss
Dr. Sergey Terushkin, MD, FACS, is a board-certified surgeon specializing in metabolic disease, bariatric surgery, and medical weight management. He focuses on evidence-based therapies for obesity and type 2 diabetes, integrating advanced incretin treatments with long-term lifestyle strategies for adult and pediatric patients.
Useful Links:
This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Mounjaro® (tirzepatide) is FDA-approved for children and adolescents aged 10 years and older with type 2 diabetes, as well as for adults with type 2 diabetes, and must be prescribed by a licensed healthcare provider. The medication may not be appropriate for all patients. Results vary, and all medical decisions should be made in consultation with a qualified medical professional.
Real people, REAL RESULTS! Check out a few of the many people that we have helped reach their ideal weight goals over the years.
